Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa‐2a
Vicente Carreño, Patrick Marcellin, Stephanos Hadziyannis, Javier Salmerón, Moisés Diago, Geoge E. Kitis, Irene Vafiadis, Solko W. Schalm, Friederike Zahm, Félix Manzarbeitia, F. Javier Jiménez, Juan Antonio Quiroga – 30 December 2003 – Fifty‐seven patients with chronic hepatitis B, hepatitis B virus (HBV) e antigen (HBeAg) and HBV DNA positivity, and aminotransferase elevation despite a previous course of any type of adequate interferon alfa (IFN‐α) therapy were included in a multicenter prospective randomized controlled trial.